← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cytoagents, Inc.
Pittsburgh, PA
$6,975,379
Total funding
4
Grants
Funding over time
peak $2.3M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,975,379 · 4
By mechanism
R44$6,975,379 · 4
Investigators at Cytoagents, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy$1,313,567
R44 · FY2025 · CA
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients$1,005,131
R44 · FY2025 · CA
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia$1,000,000
R44 · FY2021 · AI
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia$1,000,000
R44 · FY2022 · AI
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients$994,859
R44 · FY2024 · CA
Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia$848,308
R44 · FY2020 · AI
Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia$813,514
R44 · FY2021 · AI